EMPA-REG OUTCOME
Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 7,020 patients with type 2 diabetes and cardiovascular disease, empagliflozin reduced cardiovascular death compared with placebo.
N
7.020
Design
Double-blind RCT
Endpunkt
CV death, MI or stroke
Relevanz
1
Ergebnis3-point MACE HR 0.86; CV death down 38 %; HF hospitalisation down 35 %.
Zinman B, et al. N Engl J Med. 2015;373(22):2117-2128. 10.1056/NEJMoa1504720
Diskussion & Kritik
First cardiovascular-outcomes trial to show an SGLT2-inhibitor benefit — unexpectedly driven by heart failure and CV death, launching the SGLT2i era.